Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Draft Guidance Paves Way For Collecting Clinical Study Data Via Digital Health Technologies

Executive Summary

The US FDA released draft guidance on how device makers, investigators and other stakeholders can use digital health solutions to collect data from clinical study participants remotely. Comments are due to the agency by 22 March 2022.

You may also be interested in...



CES 2022: Defying Omicron, World’s Biggest Tech Show Goes Live In Las Vegas

CES 2022 is missing some marquee names due to the coronavirus surge, but there’s still plenty to take in at the intersection of digital health and consumer tech. In this roundup, Medtech Insight highlights some standouts, with commentary from company leaders.

JPM 2022: Boston Scientific, Inspire, Nuvasive, Vericel

The annual J.P. Morgan Healthcare Conference includes presentations from major medtech companies describing their experience in 2021 and expectations for 2022 as they continue to cope with the impact of the Omicron surge. Here are some of the highlights from the presentations on the third day of the meeting.

JPM 2022: Abbott, iRhythm, Novocure, Zimmer Biomet

The annual J.P. Morgan Healthcare Conference includes presentations from major medtech companies describing their experience in 2021 and expectations for 2022 as they continue to cope with the impact of the Omicron surge. Here are some of the highlights from the presentations on the second day of the meeting.

Topics

UsernamePublicRestriction

Register

MT144878

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel